# NIH Reporter #4R44NS137868-02

Validation of a novel treatment for glioblastoma using oncolytic Zika virus

**Recipient:** UP ONCOLYTICS, INC.

**Award Amount:** $1,268,244.00
**Ceiling:** $1,268,244.00

**Awarded:** September 17, 2026

**Identifier:** 4R44NS137868-02

Award for developing oncolytic Zika virus strains as a novel treatment for glioblastoma, funded by NINDS with $1,268,244, focusing on IND-enabling studies to advance to clinical trials.

### Description

This project aims to develop and test oncolytic Zika virus strains for glioblastoma treatment, involving IND-enabling studies and preclinical testing. The treatment targets glioblastoma multiforme (GBM), a highly aggressive brain tumor with poor prognosis, using specialized immunotherapy with oncolytic viruses that can cross the blood brain barrier and target GBM cells specifically. The project is funded by the National Institute of Neurological Disorders and Stroke (NINDS) under NIH, with a total award amount of $1,268,244, and is scheduled from September 20, 2024 to June 30, 2028.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11204793)